Cost-effectiveness analysis: should it be required for drug registration and beyond?
Cost-effectiveness analysis (CEA) is applied in situations where trade-offs exist, typically, greater benefit for an increased cost over an alternative therapy or strategic option versus usual care. CEA is useful where a new strategy is more costly but expected to be more effective or where a new strategy is less costly but less effective. A good example for the relevance of CEA is the unanimous recommendation of a US federal vaccine advisory panel to vaccinate 11-year-old girls against cervical cancer. This recommendation was at least partly because of data showing the relative cost-effectiveness of HPV vaccine. In this era of finite budgets, CEA may facilitate drug development, drug approval, patient segmentation and pricing model development throughout the drug lifecycle continuum.
Arnold
Renée J Goldberg
RJ
Arnold Consultancy & Technology LLC, 1 Penn Plaza - 36th floor, New York, NY 10119, United States. rarnold@arnoldllc.com
D003362:Cost-Benefit Analysis; D003657:Decision Making; D017277:Drug Approval; D004345:Drug Industry; D005260:Female; D006801:Humans; D053918:Papillomavirus Vaccines / Q000191:economics / Q000276:immunology; D012042:Registries; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control
D053918:Papillomavirus Vaccines